Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964905 | 0.94 | CHRM1 (0.68) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL4210140 | 0.90 | GAA (0.71) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL14810985 | 0.88 | CHRM1 (0.76) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL7018944 | 0.87 | CHRM1 (0.59) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL8353063 | 0.84 | CHRM1 (0.70) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL20066228 | 0.82 | CHRM1 (0.53) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL18825173 | 0.82 | CHRM1 (0.68) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL14964843 | 0.82 | CHRM1 (0.68) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL18849584 | 0.82 | CHRM1 (0.68) | CHRM1TP53TDP1GAAALDH1A1 | |
| SCHEMBL12967015 | 0.82 | MAPK1 (0.70) | CHRM1TP53TDP1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10413553-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-08 | — | — | US | disclosed |
| US-9079894-B2 | Heteroaryl compounds as 5-HT4 receptor ligands | SUVEN LIFE SCIENCES LTD (IN) | 2015-07-14 | — | — | US | disclosed |
| EP-2758394-B1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-02-18 | — | — | EP | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2758394-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2014-07-30 | — | — | EP | disclosed |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-07-03 | — | — | US | disclosed |
| WO-2013042135-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885TP53 3392/4885TDP1 2101/4885 |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885TP53 3392/4885TDP1 2101/4885 |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885TP53 3392/4885TDP1 2101/4885 |
| US-10973832-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885TP53 3392/4885TDP1 2101/4885 |
| US-10413553-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885TP53 3392/4885TDP1 2101/4885 |
| US-20150283125-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | CHRM1 403/4885TP53 4848/4885TDP1 4043/4885 |
| US-20140187581-A1 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS | HTR4, HTR5A, HTR2C | CHRM1 403/4885TP53 4848/4885TDP1 4043/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885TP53 3392/4885TDP1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.